RecruitingNCT06945978

Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)

Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer

Sponsor

Benedito Mauro Rossi

Enrollment

60 participants

Start Date

Jan 21, 2025

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Metastasis Epigenetic

Summary

This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Patients diagnosed with metastatic PDAC;
Patients who will start treatment with FOLFIRINOX;
years or older;
Who agree to participate in the study by signing the Informed Consent Form;

Exclusion Criteria2

Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;